Comparing the current results to its competitors, Dmk Pharmaceuticals reported Revenue decrease in the 3 quarter 2023 year on year by -99.4 %, faster than the overall decrease of Dmk Pharmaceuticals's competitors by -7.3 %, recorded in the same quarter.
Dmk Pharmaceuticals Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 3.18 %
December 21, 2023
DMK Pharmaceuticals Secures Full Rights to Commercialize ZIMHI and Seeks Lucrative PartnershipsIn a strategic move to expand revenue generation, DMK Pharmaceuticals has successfully regained full rights to commercialize their highly anticipated product, ZIMHI. This significant development allows the company to establish a stronger foothold in the pharmaceutical market and pursue commercialization partnerships in the United States, Canada, and Europe. ZIMHI, a groundbreaking medical innovation, holds enormous potential in revolutionizing healthcare practices. With its unique features and promising results, DMK Pharmaceuticals aims to maximize ZIMHI s market reach through strategic collaborations with industry...
Publicly Traded Peers of Dmk Pharmaceuticals Corporation
Allarity Therapeutics Inc Share Performance
-10.13%
This Quarter
Allarity Therapeutics Inc
Profile
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Sources:
Dmk Pharmaceuticals Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dmk Pharmaceuticals Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
